A5039278929- Monoclonal and Polyclonal Antibodies Research
- Chronic Lymphocytic Leukemia Research
- Inflammatory Bowel Disease
- Rheumatoid Arthritis Research and Therapies
- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
- Systemic Lupus Erythematosus Research
- Immunodeficiency and Autoimmune Disorders
- Renal Transplantation Outcomes and Treatments
- Biosimilars and Bioanalytical Methods
- Microscopic Colitis
- HER2/EGFR in Cancer Research
- Antibiotics Pharmacokinetics and Efficacy
- Pharmacogenetics and Drug Metabolism
- Lymphoma Diagnosis and Treatment
- Pharmaceutical studies and practices
- Protein purification and stability
- Inhalation and Respiratory Drug Delivery
- Spondyloarthritis Studies and Treatments
- Hepatocellular Carcinoma Treatment and Prognosis
- Pharmacological Effects and Toxicity Studies
- Drug Transport and Resistance Mechanisms
- Lung Cancer Treatments and Mutations
- Statistical Methods in Clinical Trials
- Autoimmune and Inflammatory Disorders Research
Université de Tours
2016-2025
Centre Hospitalier Universitaire de Tours
2016-2025
Inserm
2006-2025
Centre National de la Recherche Scientifique
2010-2019
Thion Medical (France)
2019
Hôpital Bretonneau
2002-2017
Karolinska Institutet
1992-2016
Karolinska University Hospital
1992-2016
Laboratoire de Biophotonique et Pharmacologie
1998-2015
Bon Secours Hospital
2015
Abstract The FCGR3A gene dimorphism generates two allotypes: FcγRIIIa-158V and FcγRIIIa-158F. genotype homozygous for (VV) is associated with higher clinical response to rituximab, a chimeric anti-CD20 IgG1 used in the treatment of B lymphoproliferative malignancies. Our objective was determine whether this genetic association relates rituximab-dependent cytotoxicity mediated by FcγRIIIa/CD16a+ cells. number CD16+ circulating monocytes, T cells, natural killer (NK) cells 54 donors first...
The only treatment available to restore normal cardiac output in patients with hereditary hemorrhagic telangiectasia (HHT) and failure is liver transplant. Anti-vascular endothelial growth factor treatments such as bevacizumab may be an effective treatment.To test the efficacy of reducing high severe hepatic forms HHT assess improvement epistaxis duration quality life.Single-center, phase 2 trial national recruitment from French Network. Patients were 18 70 years old had confirmed HHT,...
Crohn's disease (CD)–associated dysbiosis could predispose patients to relapse. Gut microbiota composition of from the prospective cohort study designed identify predictive factors clinical relapse after infliximab discontinuation (STORI Study) was investigated determine impact in CD Fecal samples 33 with this were collected at baseline, 2 months, 6 and end follow-up period (19 relapsers 14 nonrelapsers). Healthy volunteers subjects (n = 29) used as a control group. The fecal assessed using...
Summary Aim : To test the hypothesis of an association between polymorphism in FCGR3A (the gene coding for FcγRIIIa, which is expressed on macrophages and natural killer cells, involved antibody‐dependent cell‐mediated cytotoxicity has recently been associated with a positive response to rituximab, recombinant immunoglobulin G1 antibody used non‐Hodgkin's lymphomas) infliximab Crohn's disease. Methods FCGR3A‐ 158 was determined using allele‐specific polymerase chain reaction assay 200...
Infliximab, a chimeric monoclonal antibody, has profoundly modified the treatment of several inflammatory diseases, but no satisfactory description its pharmacokinetics is available. The objective this study to describe infliximab and explore sources interindividual variability. Thirty-three chronic bowel disease patients were studied. Infliximab serum concentrations, obtained during therapeutic drug monitoring, analyzed using population approach. Influence sex, weight, age, concomitant...
A proportion of patients receiving infliximab have antibodies toward (ATI), which are associated with increased risk infusion reaction and reduced response to treatment. We studied the association concentration at treatment initiation development ATI as well presence maintenance infliximab. All rheumatoid arthritis (RA) or spondyloarthritis (SpA) beginning in December 2005 were retrospectively followed until January 2009 discontinuation. Trough serum concentrations measured each visit. The...
It is well known that several inflammatory cytokines can modulate hepatocellular gene expression in a complex physiological process as the hepatic acute-phase response. Since hepatitis B virus (HBV) characteristically induces vigorous lymphomononuclear response liver during acute and chronic hepatitis, it possible HBV may also be modulated by one or more of produced these cells. Using bacterial lipopolysaccharide (LPS) surrogate inducer vivo, we have tested this hypothesis transgenic mouse...
Cetuximab is an anti-epidermal growth factor receptor monoclonal antibody used in the treatment of colorectal and head neck cancers. Part interindividual differences response may be explained by variability pharmacokinetics. An assay measuring cetuximab serum concentrations therefore needed. enzyme-linked immunosorbent was developed using microtiter plates sensitized with a recombinant human epidermal extracellular domain. Lower upper limits quantitation limit detection were determined....
Abstract Purpose: An ancillary phase II study was conducted to interindividual variability in cetuximab pharmacokinetics and its influence on progression-free survival (PFS) metastatic colorectal cancer patients cotreated with irinotecan 5-fluorouracil. Experimental Design: Ninety-six received as an infusion loading dose of 400 mg/m2 followed by weekly infusions 250 mg/m2. Doses 5-fluorouracil were adjusted individually. Cetuximab concentrations measured ELISA. Compartmental pharmacokinetic...
Aims This study aimed at describing adalimumab pharmacokinetics ( PK ) and the concentration–effect relationship of using pharmacokinetic–pharmacodynamic PK–PD modelling in patients with rheumatoid arthritis RA ). Methods Adalimumab data were obtained from a multicentric observational study. (40 mg) was administered subcutaneously every other week, its described one‐compartment model. The between concentration C ‐reactive protein CRP an indirect response model inhibition input, whereas...
Infliximab, an anti-tumour necrosis factor-α monoclonal antibody, is indicated in rheumatoid arthritis (RA). Our objective was to evaluate the influence of sources infliximab pharmacokinetic variability RA.Eighty-four patients treated with for RA were included a prospective noncomparative study. They analysed between two consecutive infusions. Infliximab concentrations measured before infusion, 2 h, 1 and 4 weeks after infusion immediately next infusion. described using two-compartment...
Background: Colorectal cancer (CRC) is a highly devastating cancer. Ca2+-dependent channels are now considered key regulators of tumor progression. In this study, we aimed to investigate the association non-voltage gated Ca2+ and potassium (KCa) with CRC using transcriptional profile their genes. Methods: We selected total 35 genes covering KCa KCNN1–4, KCNMA1 subunits KCNMB1–4, endoplasmic reticulum (ER) calcium sensors STIM1 STIM2, ORAI1–3 family cation TRP (TRPC1–7, TRPA1, TRPV1/2,4–6...